argenx

Myositis is a group of autoimmune conditions that causes muscle inflammation and symptoms such as muscle weakness, fatigue, pain, and difficulty with daily activities. Learn more about our dedication to the myositis community: https://bit.ly/3VLFXbg #TogetherWeDiscover

While in college, Craig began experiencing symptoms of chronic inflammatory demyelinating polyneuropathy (CIDP). Initially misdiagnosed with Guillain-Barré syndrome, Craig took an active role in his health, working with his neurologist to reach a CIDP diagnosis. Hear more about how Craig has remained positive and resilient through challenges along his journey: https://bit.ly/3ZAt8BM #TogetherWeDiscover

The resilient spirit of patients with rare diseases, such as chronic inflammatory demyelinating polyneuropathy (#CIDP), fuels our commitment to improve the lives of CIDP patients.     #TogetherWeDiscover

We’re proud to share that argenx and our CEO Tim Van Hauwermeiren were awarded this year’s INSEAD Innovator Prize by the INSEAD Alumni Association of Belgium. This award recognizes our innovative mission, entrepreneurial spirit, and growth into a global immunology company transforming patient lives worldwide. At the gala, Tim was joined by Bart Lambrecht, Christina Takke, and MG Patient Lut Allard to discuss: ➡️ argenx’s approach to co-creation in the lab ➡️ The value of diversity in collaboration ➡️ The impact of innovation on patient lives Learn how innovation fuels our work to transform patient lives: https://bit.ly/4gc4gaz #TogetherWeDiscover

Understanding myositis, an autoimmune condition affecting approximately 50,000 people in the U.S., is vital to our work to investigate treatment options. For Melissa, living with myositis has meant learning to manage her symptoms of fatigueand pain, while finding support from others with myositis.     Learn more about how we support this patient community: https://bit.ly/3Vjlv1m   #TogetherWeDiscover 

Understanding the distinctions between neuromuscular diseases is key to advancing targeted therapies. Recently on the DNA Today Podcast, Dr. Hanns Lochmuller, the Principal Investigator for our ARGX-119 program, breaks down key differences between congenital myasthenic syndromes (CMS) and myasthenia gravis (MG). Hear Dr. Lochmüller’s insights on the nuances of each condition and what they mean for patients and research in the full interview: https://bit.ly/49ffHM5    #TogetherWeDiscover

Supporting patients is always at the forefront of our work to translate our science into innovative treatment options. As Tony Rosenberg shares, this dedication to patients was evident from day one.    Learn more about our patient commitment: https://bit.ly/3ZmbAKG #TogetherWeDiscover

Driving innovation in autoimmune disease treatment begins with deepening our understanding of conditions through meaningful connections with the patient community. Bilal's journey with thyroid eye disease (TED) highlights the value of patient insights in advancing care and research. To learn more about Bilal's experience, read his story below ⬇️ #TogetherWeDiscover

We’re excited to announce a partnership with Steritas to advance the evidence supporting novel steroid-sparing therapeutics across our immunology development programs.    We look forward to collaborating with Steritas to support the development of innovative steroid-sparing treatments for autoimmune diseases. Learn more: https://bit.ly/4eMvvqG   #TogetherWeDiscover 

Today we announced the decision to continue the ongoing Phase 2/3 ALKIVIA study in adults with idiopathic inflammatory myopathies (IIM or myositis) in each of the three myositis subtypes.    We are advancing our understanding of the pathophysiology of myositis, further establishing the causal role of IgG antibodies in the disease. Precision therapies now take this understanding one step further.    Learn more: https://bit.ly/4eKfiCd   #TogetherWeDiscover